TY - JOUR A2 - Wang, Fu AU - Fang, Dan-Dong AU - Huang, Wei AU - Cheng, Gang AU - Liu, Xiao-Nan AU - Liu, Shi-Min AU - Hou, Bao-Sen AU - Mao, Jian AU - Zhou, Hu PY - 2021 DA - 2021/12/23 TI - Clinicopathological and Prognostic Significance of ABCC3 in Human Glioma SP - 1827992 VL - 2021 AB - Glioma is the most common malignant primary brain tumor with an inferior survival period and unsatisfactory prognoses. Identification of novel biomarkers is important for the improvements of clinical outcomes of glioma patients. In recent years, more and more biomarkers were identified in many types of tumors. However, the sensitive markers for diagnoses and prognoses of patients with glioma remained unknown. In the present research, our team intended to explore the expression and clinical significance of ABCC3 in glioma patients. Sequential data filtration (survival analyses, independent prognosis analyses, ROC curve analyses, and clinical association analyses) was completed, which gave rise to the determination of the relationship between glioma and the ABCC3 gene. Clinical assays on the foundation of CGGA and TCGA datasets unveiled that ABCC3 expression was distinctly upregulated in glioma and predicted a shorter overall survival. In the multivariable Cox analysis, our team discovered that the expression of ABCC3 was an independent prognosis marker for both 5-year OS (HR = 1.118, 95% CI: 1.052–1.188; P<0.001). Moreover, our team also studied the association between ABCC3 expression and clinical features of glioma patients, finding that differential expression of ABCC3 was remarkably related to age, 1p19q codeletion, PRS type, chemo status, grade, IDH mutation state, and histology. Overall, our findings suggested ABCC3 might be a novel prognosis marker in glioma. SN - 1687-8450 UR - https://doi.org/10.1155/2021/1827992 DO - 10.1155/2021/1827992 JF - Journal of Oncology PB - Hindawi KW - ER -